Faculty Opinions recommendation of Multi-institutional validation of the predictive value of Ki-67 labeling index in patients with urinary bladder cancer.

Author(s):  
Dieter Jocham ◽  
Ingo Kausch
2009 ◽  
Vol 101 (2) ◽  
pp. 114-119 ◽  
Author(s):  
V. Margulis ◽  
Y. Lotan ◽  
P. I. Karakiewicz ◽  
Y. Fradet ◽  
R. Ashfaq ◽  
...  

2009 ◽  
Vol 181 (4S) ◽  
pp. 69-69
Author(s):  
Vitaly Margulis ◽  
Yair Lotan ◽  
Pierre I Karakiewicz ◽  
Yves Fradet ◽  
Raheela Ashfaq ◽  
...  

2020 ◽  
Vol 64 (2) ◽  
Author(s):  
Stanislav Ziaran ◽  
Stefan Harsanyi ◽  
Katarina Bevizova ◽  
Zuzana Varchulova Novakova ◽  
Branislav Trebaticky ◽  
...  

Although the incidence varies with age and gender, urothelial bladder cancer is a relatively frequently occurring malignancy with variable clinical behavior that often has high recurrence rates. In this study, we analyzed the tumor tissues of 224 patients with pTa, pT1, and pT2 urinary bladder cancer. We performed a histomorphologic analysis and immunohistochemistry for p53, Ki-67, and E-cadherin, which were selected as markers of the malignant process. For pTa and pT1, univariate analyses of cancer-specific survival (CSS), progression-free survival (PFS), and recurrence-free survival (RFS) were calculated using the Kaplan-Meier method, the log-rank test and Cox regression. Multivariate analysis was performed by a Cox regression analysis. Ki-67 (P<0.001) was significantly associated with CSS, but the highest association was shown for E-cadherin (P<0.001). For pT1 and pTa, the Kaplan-Meier analysis and the log-rank test revealed significantly worse PFS for patients with higher levels of Ki-67 (P<0.001) and lower levels of E-cadherin (P<0.001). Based on these obtained results, it can be clearly stated that Ki-67 and E-cadherin expression levels are associated with CSS, PFS and RFS. The clinical utility of these markers is valuable for pTa and pT1 urinary bladder cancer and should be further verified with prospective multi-center trials.


2021 ◽  
Vol 39 (15_suppl) ◽  
pp. e16507-e16507
Author(s):  
Sven Kurbel ◽  
Branko Dmitrovic ◽  
Mate Matić ◽  
Damir Vrbanec

e16507 Background: The aim was to define IHC changes between the two subsequent urinary bladder cancers (UBC). Methods: IHC data on EGFR, HER2, HER3, Ki-67, MLH1, MSH2, MSH6 and PMS2 in 113 UHC from 24 male and 9 female patients (1 to six recurrences) were used. Except for the Ki-67 value, other markers were stratified: “0” for no positive cells; “1” < = 10% positive cells; “2” 1%-30% positive cells; and “3” 31%-100% positive cells. Data of consecutive tumors were paired in 80 processes of recurrence (PoR). Changes between the latter and the former tumor were calculated: in +/- % for Ki-67 values, and as integer sums of absolute changes in expression for HER markers and for Lynch markers. EM clustering was applied for recognition of relevant IHC changes. Results: Three aspects were tested: the speed of recurrence, was it the first, or later recurrence and whether PoRs depended on the total number of tumors in that patient. Early and late PoRs clustered along the Lynch score, while the intermediate clustered along the delta Ki-67 value. The first PoRs clustered along the HER score and all subsequent PoRs depended on the Lynch score. Conclusions: Even in this limited group of patients Lynch and HER markers showed complex differences between early and late recurrent tumors. The speed of the recurrence and changes of IHC features depended mainly on the rate of change in Lynch markers, suggesting that they should be tested as predictors of UBC recurrence.[Table: see text]


2005 ◽  
Vol 173 (4S) ◽  
pp. 211-211
Author(s):  
Loleta D. Harris ◽  
Tomasz Tuziak ◽  
Jorge De Lo Cerda ◽  
Anita L. Sabichi ◽  
Ying Yang ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document